Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Our recent discovery of the substituted cyclobutane Boc5, one of the first non-peptidic agonists at glucagon-like peptide-1 receptors, offers the potential of combining oral availability with full agonism capable of eliciting antidiabetic and antiobesity effects. The present study was aimed at determining the in vivo pharmacologic properties of Boc5 in both normal and diabetic mice following chronic administration, with emphasis on glycemic control and weight loss. METHODOLOGY/PRINCIPAL FINDINGS: C57BL/6J and db/db mice were treated daily with Boc5 for 4 weeks and a range of pharmacologic parameters, including hemoglobin A1c, intraperitoneal glucose tolerance, insulin tolerance, fasting insulin and leptin levels, food intake, body weight and fat mass, were assessed before and after the treatment. Effects on food intake, gastric emptying, and insulinogenic index were also investigated in animals acutely administered with Boc5. Boc5 (3 mg) was able to induce a durable restoration of glycemic control (normalization of both hemoglobin A1c and intraperitoneal glucose tolerance) in db/db mice, following 4 weeks of daily administration. As with peptidic glucagon-like peptide-1 receptor agonists, its glycemic benefit and weight (fat) loss were associated with dose-dependent effects that included reduction in food intake, slowing of gastric emptying (both of which reduce nutrient-drive at beta-cells), stimulation of insulin secretion (which was glucose-dependent), and elevation in insulin sensitivity. There was little effect on normal mice treated in the same manner. CONCLUSIONS/SIGNIFICANCE: Our findings suggest that Boc5 is the only non-peptidic molecule reported thus far to simultaneously activate this spectrum of antidiabetic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“QUICKI, similarly derived from fasting insulin and glucose, is an index of insulin sensitivity that correlates with clamp-derived measures in mice [34].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Glucose-dependent insulinotropic peptide (GIP) receptor agonists powerfully induce glucose-dependent insulin secretion [14], but have no intrinsic effect on food intake, gastric emptying [15], glucagon secretion [16], or insulin sensitivity [17].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., & Fuchs, Z. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111776 · Cited by 1,465 · cited 1×
“recognized for 40 years [3,4].”
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“, chronic GLP-1R agonism exerts an insulin-sensitizing effect in humans”
BackgroundPrevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“Even though plasma insulin is typically reduced by exogenous GLP-1R agonists through their several glucose-lowering actions, amplification of insulin secretion can be revealed with indices such as HOMA-B [45] and the insulinogenic index [46].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 1×
“Such an effect in liver is further evidenced by reversal of hepatic steatosis and oxidative stress in ob/ob mice following exenatide treatment [43], and is supported in type 2 diabetic patients by amelioration of surrogate markers of nonalcoholic fatty liver disease [44].”
BackgroundRegulation of fatty acid homeostasis in cells: Novel role of leptin
Unger, R. H., Zhou, Y.-T., & Orci, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2327 · Cited by 435 · cited 1×
“A leptin-mediated feedback that limits lipotoxicity by confining triglyeride to adipocytes [41] may be overwhelmed in hypernutrition.”
BackgroundBuse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Self-citationThe structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“As a non-peptidic oral GLP-1R agonist, Boc5, invoked sustained glycaemic control and weight loss in diabetic db/db mice [116,117], DPP-4-resistant GLP-1-attached micro-beads (a modi fi ed polymer preparation) also improved glucose tolerance in diabetic db/db animals [118].”
BackgroundDeepCPI: A Deep Learning-Based Framework for Large-Scale in Silico Drug Screening
Wan, F., Zhu, Y., Hu, H., Dai, A., Cai, X., Chen, L., Gong, H., Xia, T., Yang, D., Wang, M.-W., et al. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.04.003 · Cited by 92
Self-citation
Metadata
- Authors
- Su, H., He, M., Li, H., Liu, Q., Wang, J., Wang, Y., Gao, W., Zhou, L., Liao, J., Young, A. A., & Wang, M.-W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-08-06
- Volume
- 3
- Issue
- 8
- Pages
- e2892
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1988009825
- Cited by
- 47
- References
- 11
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0002892
- The paper
- Su, H., He, M., Li, H., Liu, Q., Wang, J., Wang, Y., Gao, W., Zhou, L., Liao, J., Young, A. A., & Wang, M.-W. (2008). Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0002892
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.